157 related articles for article (PubMed ID: 17045088)
1. Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
Kim WY; Kaelin WG
Semin Oncol; 2006 Oct; 33(5):588-95. PubMed ID: 17045088
[TBL] [Abstract][Full Text] [Related]
2. [Current strategies in the treatment of renal-cell cancer: targeted therapies].
Trigo JM; Bellmunt J
Med Clin (Barc); 2008 Mar; 130(10):380-92. PubMed ID: 18381031
[TBL] [Abstract][Full Text] [Related]
3. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
4. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
5. mTOR pathway in renal cell carcinoma.
Hanna SC; Heathcote SA; Kim WY
Expert Rev Anticancer Ther; 2008 Feb; 8(2):283-92. PubMed ID: 18279068
[TBL] [Abstract][Full Text] [Related]
6. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
Flaherty KT; Puzanov I
Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of hypoxia inducible factor in renal cell carcinoma.
Smaldone MC; Maranchie JK
Urol Oncol; 2009; 27(3):238-45. PubMed ID: 19414111
[TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin inhibition.
Dutcher JP
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6382S-7S. PubMed ID: 15448035
[TBL] [Abstract][Full Text] [Related]
9. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
Choueiri TK; Bukowski RM; Rini BI
Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
[TBL] [Abstract][Full Text] [Related]
10. Combination targeted therapy in advanced renal cell carcinoma.
Sosman J; Puzanov I
Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
[TBL] [Abstract][Full Text] [Related]
11. Understanding the importance of smart drugs in renal cell carcinoma.
Patard JJ; Rioux-Leclercq N; Fergelot P
Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
Miyazawa M; Yasuda M; Fujita M; Kajiwara H; Hirabayashi K; Takekoshi S; Hirasawa T; Murakami M; Ogane N; Kiguchi K; Ishiwata I; Mikami M; Osamura RY
Pathol Int; 2009 Jan; 59(1):19-27. PubMed ID: 19121088
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
[TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
Costa LJ; Drabkin HA
Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
[TBL] [Abstract][Full Text] [Related]
15. Renal cell cancer.
Hutson TE; Figlin RA
Cancer J; 2007; 13(5):282-6. PubMed ID: 17921725
[TBL] [Abstract][Full Text] [Related]
16. Update on the medical treatment of metastatic renal cell carcinoma.
Ravaud A; Wallerand H; Culine S; Bernhard JC; Fergelot P; Bensalah K; Patard JJ
Eur Urol; 2008 Aug; 54(2):315-25. PubMed ID: 18485581
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA
Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
[TBL] [Abstract][Full Text] [Related]
18. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
[TBL] [Abstract][Full Text] [Related]
19. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
[TBL] [Abstract][Full Text] [Related]
20. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
Rini BI; Flaherty K
Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
